MRES: M2Bio
Sciences Enters into Letter of Intent to
Acquire Crypto
Exchange JDAX
CAPE TOWN,
SOUTH AFRICA -- June 26, 2023 -- InvestorsHub NewsWire -- Institute
of Biomedical Research Corp. (OTC
PINK: MRES) ("Institute of Biomedical Research" or the
"Company"), a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, is pleased to
share the following update:
M2Bio Sciences is thrilled
to announce the signing of a letter of intent to acquire
JDAX, a major
cryptocurrency platform facilitating seamless exchange, trading,
and secure storage of digital currencies.
Functioning
as a cutting-edge digital marketplace, JDAX empowers users to buy,
sell, and hold a wide range of cryptocurrencies. Moreover, it
facilitates essential activities such as managing digital wallets,
executing trades, and accessing comprehensive market
data.
JDAX, the
Johannesburg Digital Assets Exchange, represents a notable South
African Fintech company immersed in the realms of Blockchain, Web3,
and Decentralized Finance (DeFi) technologies. By positioning
itself at the forefront of these advancements, M2Bio aims to
accelerate the traditionally challenging and time-consuming process
of natural product drug discovery. Through collaborations with
prestigious universities and the support of multiple funded
research chairs, the M2Bio Research Team is engaged in the
extraction of bioactive compounds from an extensive collection of
African plants renowned for their potential efficacy. Leveraging
novel extraction methods and AI models, M2Bio exponentially
enhances the pace of discovery and characterization of potentially
bioactive compounds.
At this
opportune moment, M2Bio aligns itself with the rapid progress of AI
and its broad applications. The acquisition of JDAX is an integral
part of M2Bio's overarching strategy to establish a
humanity-centric enterprise. By leveraging JDAX's blockchain
technology, M2Bio envisions a future where research projects can be
tokenized. This allows for decentralized ownership and the
potential issuance of Non-Fungible Tokens (NFTs) representing
fractional ownership rights over the discovered molecules.
Ze-ev Krein, an
interdisciplinary scientist and the founder of JDAX, will guide
M2Bio's drug discovery program and will spearhead the development
of smart contracts that enable global communities to actively
participate in and potentially hold ownership stakes in the
transformative discoveries arising from M2Bio's research
efforts.
Ze-ev Krein, drawing
on his background in medicinal chemistry, computer science,
economics, and law, expressed his vision for JDAX, stating:
"Our ultimate goal has always been to create a platform that funds
projects capable of bringing about impactful changes for humanity.
M2Bio's acquisition will catalyze this ambition. As a scientist, I
firmly believe that the most significant obstacle to scientific
discovery lies not in the capabilities of researchers, but in the
rigidity of financial systems. AI, Web3, and decentralized finance
possess the power to dismantle these primitive boundaries. In this
unique endeavor, we aim to lead the way in revolutionizing
phytomedicine discovery."
Jeff Robinson, M2Bio Sciences, Inc CEO
added:
"At M2Bio we are always working on finding unique ways to deploy
cutting-edge technologies in order to advance medicine. Altcoins
and NFTs are here to stay and are slowly but surely becoming part
of our everyday lives.
Creating an NFT using the crystal structure of a molecule can serve
as a fascinating way to merge science and art, showcasing the
beauty and complexity of molecular structures in a digital medium.
These representations can include the three-dimensional arrangement
of atoms, molecular bonds, and the overall crystal lattice
structure. It will appeal to a wide range of audiences, including
scientists, art enthusiasts, collectors, and individuals with an
interest in both fields. In addition, it plays
well into the human needs for ownership and authenticity.
The NFT serves as a unique digital asset that can include relevant
information such as the name of the compound, its therapeutic
potential, key research details, and associated images or videos.
And the blockchain's immutable nature ensures that the ownership
history and details associated with the NFT are securely recorded
and verifiable. Without a doubt, this space will become a
trillion-dollar opportunity. It feels great to be offering a
real-world use case scenario to the world and not just another
fatigued ape."
The closing
of the acquisition is expected to take place by July 31, 2023, or
sooner.
About Institute of
Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research
Corp, is a nutraceutical biotechnology company focused on
alternative plant-based cannabinoids, medical psilocybin and mental
health therapeutic research powered by artificial intelligence, and
evidence-based sustainable products and solutions, that develops
and commercializes a range of CBD and mushrooms-based products
under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as
artificial intelligence powered nutrition products and solutions
under the M2Biome brand. In addition, our research and clinical
trials with psilocybin are aimed at new therapies that will help
patients who suffer from alcohol addiction, mental illness, and
cardiovascular diseases. Our mission is to advance botanical-based
medicine to the forefront by deploying best-practice science and
medicine, clinical research, and emerging technologies such as
artificial intelligence. The Company is traded on the
Over-the-Counter Bulletin Board of NASDAQ under the trading symbol
"MRES".
Publicly traded Company (OTC
Pink: MRES)
www.m2bio.co
jeff@m2bio.co
+27 72 333 2148
Find M2Bio™ on
social media
Facebook:
M2Bio
Instagram:
M2bio.Sciences
LinkedIn:
M2Bio
Twitter:
@M2bio
Forward-Looking
Statements
Safe Harbour
Statement - In addition to historical information, this press
release may contain statements that constitute forward-looking
statements within the meaning of the Securities Act of 1933 and the
Securities Exchange Act of 1934, as amended by the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements contained in this press release include the intent,
belief, or expectations of the Company and members of its
management team with respect to the Company's future business
operations and the assumptions upon which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future
performance, involve risks and uncertainties and that actual
results may differ materially from those contemplated by such
forward-looking statements. Factors that could cause these
differences to include, but are not limited to, failure to complete
anticipated sales under negotiations, lack of revenue growth,
client discontinuances, failure to realize improvements in
performance, efficiency, and profitability, and adverse
developments with respect to litigation or increased litigation
costs, the operation or performance of the Company's business units
or the market price of its common stock. Additional factors that
could cause actual results to differ materially from those
contemplated within this press release can also be found on the
Company's website. The Company disclaims any responsibility to
update any forward-looking statements.